Patents by Inventor Inés Noelia Casares Lagar
Inés Noelia Casares Lagar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11560407Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: GrantFiled: April 20, 2020Date of Patent: January 24, 2023Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Inés Noelia Casares Lagar, Juan José Lasarte Sagastibelza, Teresa Lozano Moreda, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20200317733Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: ApplicationFiled: April 20, 2020Publication date: October 8, 2020Inventors: Inés Noelia CASARES LAGAR, Juan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Patent number: 10654896Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: GrantFiled: October 19, 2017Date of Patent: May 19, 2020Assignee: FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADAInventors: Inés Noelia Casares Lagar, Juan José Lasarte Sagastibelza, Teresa Lozano Moreda, Julen Oyarzabal Santamarina, Maria Obdulia Rabal Gracia
-
Publication number: 20190276496Abstract: The present invention provides peptides of general formula (I) and salts thereof, wherein: R1 and R2, taken together, form a birradical linker; and R2? is hydrogen; or, alternatively, R1 is selected from hydrogen, —C(?O)—CH2—NH—C(?O)—(C1-C5)alkyl, and —C(?O)—(C1-C20)alkyl; one of R2 and R2? is hydrogen and the other is selected from —C(?O)NR3R4, and —C(?O)OH; and R3 and R4 are same or different and are selected from hydrogen and (C1-C10)alkyl. These peptides are highly efficient in binding and inhibiting FoxP3, being efficient in inhibiting and blocking Treg cell functionality, which make them useful in the treatment of cancer. The present invention also provides constructs comprising the peptide of formula (I) as well as combinations comprising the peptide of formula (I), the construct or both.Type: ApplicationFiled: October 19, 2017Publication date: September 12, 2019Inventors: Inés Noelia CASARES LAGAR, Juan José LASARTE SAGASTIBELZA, Teresa LOZANO MOREDA, Julen OYARZABAL SANTAMARINA, Maria Obdulia RABAL GRACIA
-
Patent number: 8524860Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: GrantFiled: November 14, 2008Date of Patent: September 3, 2013Assignee: Proyecto de Biomedicina CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borrás Cuesta, Pablo Sarobe Ugarriza, Jesús Maria Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20130064790Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 8, 2012Publication date: March 14, 2013Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea MANTEROLA CAREAGA, Inés Noelia CASARES LAGAR, Nancy Díaz-Valdés Farray, Javier DOTOR DE LAS HERRERÍAS, Juan José LASARTE SAGASTIBELZA, Pablo SAROBE UGARRIZA, Jesús PRIETO VALTUEÑA, Francisco BORRÁS CUESTA
-
Patent number: 8148334Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: GrantFiled: March 27, 2008Date of Patent: April 3, 2012Assignee: Proyecto de Biomedicina Cima, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Díaz-Valdés Farray, Javier Dotor de las Herrerías, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueñ, Francisco Borrás Cuesta
-
Publication number: 20110268757Abstract: The invention relates to methods for increasing immunogenicity of an antigenic peptide by means of its covalent coupling to a modulin derived peptide (PSM, phenol soluble modulin). In particular, the binding of PSM?, PSM? and PSM? peptides to an antigen (from a pathogen or a tumor associated protein) increases the capacity of the antigen to activate an immune response in vivo.Type: ApplicationFiled: December 2, 2009Publication date: November 3, 2011Applicants: INSTITUT PASTEUR, PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Francisco Borrás Cuesta, Inés Noelia Casares Lagar, María del Carmen Durántez Delgado, Juan José Lasarte Sagastibelza, Claude Leclerc, Jesús María Prieto Valtueña, Pablo Sarobe Ugarriza
-
Publication number: 20100267623Abstract: The invention relates to peptides of general formula (I), wherein X is absent or X is present and is X14 or X14-X15, wherein X14 and X15, independently from one another, represent an amino acid; their functional variants and fragments, and their pharmaceutically acceptable salts, having the capacity to bind to scurfin and inhibit its biological activity, therefore they regulate or block the activity of regulatory T (Treg) lymphocytes. They are applicable in the treatment of infectious and neoplastic diseases.Type: ApplicationFiled: November 14, 2008Publication date: October 21, 2010Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Inés Noelia Casares Lagar, Francisco Borras Cuesta, Pablo Sarobe Ugarriza, Jesús Prieto Valtueña, Juan José Lasarte Sagastibelza
-
Publication number: 20100168015Abstract: The invention relates to peptides having the capacity to bind to interleukin-10 (IL-10) and their use in the treatment of clinical conditions or pathological disorders associated to IL-10 expression, particularly to a high IL-10 expression, for example, infectious diseases, tumors, cancers and acute damage conditions.Type: ApplicationFiled: March 27, 2008Publication date: July 1, 2010Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Lorea Manterola Careaga, Inés Noelia Casares Lagar, Nancy Diaz-Valdés Farray, Javier Dotor De Las Herrerias, Juan José Lasarte Sagastibelza, Pablo Sarobe Ugarriza, Jesús Prieto Valtueña, Francisco Borràs Cuesta